- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|No information available.|
|Summary of Clinical Use|
|The US FDA had granted breakthrough therapy designation for ocrelizumab for the treatment of primary progressive multiple sclerosis which converted to full FDA approval for the treatment of relapsing and primary progressive types of multiple sclerosis in March 2017. Phase 3 clinical trials identified that ocrelizumab produced a pronounced reduction of disease activity in multiple sclerosis patients .
Development of this antibody as a treatment for other inflammatory disorders, such as rheumatoid arthritis and systemic lupus erythematosus, and B-cell malignancies has been suspended [3-4].
|Mechanism Of Action and Pharmacodynamic Effects|
|Ocrelizumab targets CD20-positive B cells which are implicated in the inflammatory and neurodegenerative processes of multiple sclerosis (MS). By targeting these cells, the aim of this treatment is to be effective whilst leaving immune surveillance intact. A single dose of ocrelizumab has been shown to deplete the subset of highly activated CD3/CD20 positive T cells (that produce substantial quantities of proinflammatory cytokines such as TNFα, IL-1β and IL-17) that were found in all tested MS patients prior to ocrelizumab exposure . Therapeutic efficacy may therefore arise from the combined depletion of CD20 positive B and T cells. Note that rituximab also depletes this pool of T cells in MS patients .|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)